{
    "clinical_study": {
        "@rank": "13438", 
        "arm_group": {
            "arm_group_label": "study", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a diagnostic accuracy study to evaluate if two novel ultrasound (US) techniques,\n      quantitative 3D subharmonic imaging (SHI) and Subharmonic Aided Pressure Estimation\n      (SHAPE), used with an intravenous ultrasound contrast agent (Definity, Lantheus Medical\n      Imaging, Billerica, MA), can track changes in locally advanced breast cancer (LABC)\n      angiogenesis and interstitial fluid pressure (IFP), respectively, by studying women\n      undergoing neoadjuvant chemotherapy before as well as with around 10% and 60% of the\n      neoadjuvant chemotherapy treatment delivered and after completion of the neoadjuvant\n      chemotherapy treatment.  Results will be compared to MRI and pathology."
        }, 
        "brief_title": "Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females\n\n          -  Be diagnosed with T1 or greater LABC, any N and M0.\n\n          -  Be scheduled for neoadjuvant chemotherapy\n\n          -  Be at least 21 years of age.\n\n          -  Be medically stable.\n\n          -  If a female of child-bearing potential, must have a negative pregnancy test.\n\n          -  Have signed Informed Consent to participate in the study.\n\n        Exclusion Criteria:\n\n          -  Males\n\n          -  Females who are pregnant or nursing.\n\n          -  Patients with other primary cancers requiring systemic treatment.\n\n          -  Patients with any metastatic disease.\n\n          -  Patients undergoing neoadjuvant endocrine therapy.\n\n          -  Patients with known hypersensitivity or allergy to any component of Definity.\n\n          -  Patients with cardiac shunts or congenital heart defects.\n\n          -  Patients with unstable cardiopulmonary conditions or respiratory distress syndrome.\n\n          -  Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary hypertension\n             or a history of pulmonary emboli.\n\n          -  Patients who have received any contrast medium (X-ray, MRI, CT or US) in the 24 hours\n             prior to the research US exam."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115607", 
            "org_study_id": "W81XWH-12-1-0066"
        }, 
        "intervention": {
            "arm_group_label": "study", 
            "intervention_name": "Definity infusion", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast cancer", 
            "Interstitial fluid pressure", 
            "Angiogenesis", 
            "Contrast enhanced ultrasound imaging", 
            "Subharmonic imaging", 
            "Subharmonic pressure estimation"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "contact": {
                "email": "flemming.forsberg@jefferson.edu", 
                "last_name": "Flemming Forsberg, PhD", 
                "phone": "215-955-4870"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19107"
                }, 
                "name": "Thomas Jefferson University"
            }, 
            "investigator": [
                {
                    "last_name": "Annina Wilkes, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alexander Sevrukov, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tiffany Avery, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Quantitative Subharmonic Breast Imaging: Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy", 
        "overall_contact": {
            "email": "flemming.forsberg@jefferson.edu", 
            "last_name": "Flemming Forsberg, PhD", 
            "phone": "215-955-4870"
        }, 
        "overall_official": {
            "affiliation": "Thomas Jefferson University", 
            "last_name": "Flemming Forsberg, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the ability of 3D SHI and SHAPE, used with Definity, to track changes in LABC angiogenesis and IFP, respectively, by studying women undergoing neoadjuvant chemotherapy before as well as with around 10% and 60% of the neoadjuvant chemotherapy treatment delivered and after completion of the neoadjuvant chemotherapy treatment and comparing results to MRI and pathology.", 
            "measure": "Changes in biomarker assessment over treatment period", 
            "safety_issue": "No", 
            "time_frame": "Neoadjuvant chemotherapy treatment period; on average 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115607"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To compare the 3D SHI depiction of breast cancer angiogenesis in humans to CD31, an immunohistochemical predictor of angiogenesis.", 
            "measure": "SHI depiction of breast cancer angiogenesis", 
            "safety_issue": "No", 
            "time_frame": "After surgery; on average 6 months"
        }, 
        "source": "Thomas Jefferson University", 
        "sponsors": {
            "collaborator": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Thomas Jefferson University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}